Cisplatin Delivered to Prostate Cancer Cells by PLGA Nanoparticles

[Guest guest]

Nanoparticles made from polyethylene glycol (PLGA)

can be targeted to an antigen for specific delivery. In this work,

prostate specific membrane antigen (PSMA) was bioengineered into the

NP, as PSMA is expressed by prostate cancer cells even in the

metastatic and castration resistant state. A prodrug approach was used

where cisplatin is released from a Pt(IV) precursor, overcoming

problems associated with cisplatin encapsulation and allowing a

cell-targeting moiety to deliver a lethal dose of cisplatin upon

intracellular reduction, as reported by MIT and Harvard researchers in the November 11, 2008 issue of the Proceedings of the National Academy of Sciences, USA. Click on the below link for the full story:<http://www.medicalnewstoday.com/articles/132139.php>